Effect of the prokinetic drug cisapride on gastrointestinal hormone release.
The influence of the prokinetic drug cisapride on the release of gastrointestinal hormones was studied in volunteers. First, acute effects of single doses of cisapride compared with saline were investigated. Cisapride at doses of 8 mg and 20 mg intravenously significantly increased plasma concentrations of pancreatic polypeptide (hPP) by 145% and 146%, respectively. Cholecystokinin (CCK) levels were increased by 176% at 8 mg cisapride, whereas gastrin and insulin levels remained unchanged. Enhancement of PP and CCK secretion was almost completely abolished by pretreatment with 1 mg atropine. Carbachol (250 micrograms subcutaneously) increased PP release by 62% but did not affect the other hormones. Second, the influence of a 1-week treatment (10 mg three times daily, given orally) on plasma hormone levels was studied. After 1 week the postprandial CCK release was diminished by 58%. Basal levels and postprandial responses of gastrin, PP, and insulin were not altered by prolonged cisapride administration. It is concluded that acute application of cisapride stimulates secretion of PP and CCK via atropine-sensitive mechanisms and that chronic treatment with cisapride diminishes CCK release by an unknown mechanism.
D000328:Adult; D002766:Cholecystokinin / Q000378:metabolism; D020117:Cisapride; D004305:Dose-Response Relationship, Drug; D005755:Gastrins / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology*
D005755:Gastrins; D005768:Gastrointestinal Hormones; D007328:Insulin; D010880:Piperidines; D010191:Pancreatic Polypeptide; D002766:Cholecystokinin; D020117:Cisapride